← board
VALN
Valneva Austria GmbHdistress 2/10 · well-funded / low risk$4.87-1%today-60% from 52w high
Infectious Disease 2
Lead: Chikungunya Virus Infection · target Vaccine
Revenue
$31M
Liquidity
$105M
Runway
2.0 yrs
Shares 1y
0%
Price & events
-52.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-4.1%
1W
-9.8%
1M
-8.6%
3M
-50.2%
6M
-33.4%
1Y
-33.3%
2Y
-82.3%
5Y
-81.6%
All
Overview
- Market Cap
- $845.14M
- Enterprise Value
- $903.94M
- Volume
- 3.55K
- 52 Week Range
- $4.84 – $12.20
- Total Shares
- 173.54M
- Float Shares
- 73.88M
- Short %
- 0.18%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 3.62%
- RVOL
- 0.14x
- Beta
- 1.41
Pipeline stages · 2 programs
VLA1553Vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VLA1601, CpG 1018®, 3M-052-AF
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-12 | Phase 3 | VLA1553 | Chikungunya Virus Infection | 363 | active not recruiting |
| 2025-04-21 | Phase 1 | VLA1601, CpG 1018®, 3M-052-AF | Zika, Zika Virus Infection | 150 | completed |
Catalyst news & presentations · 1
- 2026-08-13earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-09-08GuggenheimBuy
- 2025-08-25HC Wainwright & Co.Buy
- 2025-05-08GuggenheimBuy
- 2025-04-15HC Wainwright & Co.Buy
- 2025-04-09HC Wainwright & Co.Buy
- 2025-04-02HC Wainwright & Co.Buy
Competitors — Vaccine
- none identified
Recent news
- 2026-07-23Valneva to report first-half results, host webcast update - Bitget
- 2026-07-22Valneva to report first half 2026 financial results on August 13 - scanx.trade
- 2026-07-22Valneva SE (Nasdaq: VALN) sets Aug. 13 webcast on 2026 first-half results - Stock Titan
- 2026-07-22Press Release: Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026 - Moomoo
- 2026-07-22Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026 - Yahoo Finance
- 2026-07-22The Ixiaro vaccine - Valneva bets on travel health demand - Ad-hoc-news.de
- 2026-07-21Valneva SE - Depositary receipt (VALN) price target decreased by 17.41% to 14.35 - MSN
- 2026-07-19The IXIARO vaccine. Valneva targets reliable Japanese encephalitis protection - Ad-hoc-news.de
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.